MedTrace Logo

Hypogonadotropic Hypogonadism in Obese Young Males

NCT03245827 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-06-29

Study results available
· View outcomes & findings →

Summary

Obesity can lead to low testosterone concentrations in young men. This study will study the effects of low testosterone in those men and the result of treating them with clomiphene.

Conditions

  • Hypogonadism, Hypogonadotropic

Interventions

DRUG

Clomiphene

clomiphene capsule 25mg twice a week

DRUG

Placebo

placebo capsule 25mg twice a week

Sponsors & Collaborators

  • Sandeep Singh Dhindsa, M.D., F.A.C.E

    lead OTHER

Principal Investigators

  • sandeep dhindsa, md · St. Louis University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-10-29
Completion
2021-10-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245827 on ClinicalTrials.gov